RSSArticle Type

Redefining Acute Relapses in Multiple Sclerosis: Implications for Phase 3 Clinical Trials and Treatment Algorithms

Redefining Acute Relapses in Multiple Sclerosis: Implications for Phase 3 Clinical Trials and Treatment Algorithms

| April 1, 2017 | 0 Comments

by Jagannadha Avasarala, MD, PhD Dr. Avasarala is with the Department of Internal Medicine, Division of Neurology, Greenville Health System, Neuroscience Associates, in Greenville, South Carolina. Innov Clin Neurosci. 2017;14(3–4):38–40

Continue Reading

Managing Your Aging  Patient Population

Managing Your Aging Patient Population

| April 1, 2017 | 0 Comments

by Ann L. McNary, JD Ms. McNary is Senior Risk Manager at PRMS, Inc. in Arlington, Virginia. Innov Clin Neurosci. 2017;14(3–4)41–44

Continue Reading

Letter to the editor: Modafinil Augmentation Therapy in Patient with Traumatic Brain Injury

Letter to the editor: Modafinil Augmentation Therapy in Patient with Traumatic Brain Injury

| April 1, 2017 | 0 Comments

Innov Clin Neurosci. 2017;14(3–4):11

Continue Reading

CNS Summit 2016 Abstracts of Poster Presentations

CNS Summit 2016 Abstracts of Poster Presentations

| February 1, 2017 | 0 Comments

Innov Clin Neurosci. 2017;14(1–2)3–23 A MESSAGE FROM THE EDITOR Dear Colleagues: Welcome to the annual CNS Summit Abstracts of Poster Presentations supplement to Innovations in Clinical Neuroscience. We are pleased to provide you with this reference guide to some of the innovative research that was presented during CNS Summit 2016, which was held October 27 […]

Continue Reading

Editor’s Message: Issue Highlights, January–February 2017

Editor’s Message: Issue Highlights, January–February 2017

| February 1, 2017 | 0 Comments

Dear Colleagues: Welcome to the January–February 2017 issue of Innovations in Clinical Neuroscience. We start our 14th year of publication strong with an interesting and diverse issue we hope you enjoy as much as we did putting it together. In the review article by Dascal et al, “Virtual Reality and Medical Inpatients: A Systematic Review […]

Continue Reading

Outcomes Assessment in Clinical Trials of Alzheimer’s Disease and its Precursors: Readying for Short-term and Long-term Clinical Trial Needs

Outcomes Assessment in Clinical Trials of Alzheimer’s Disease and its Precursors: Readying for Short-term and Long-term Clinical Trial Needs

| February 1, 2017 | 0 Comments

by Holly Posner, MD, MS; Rosie Curiel, PsyD; Chris Edgar, PhD; Suzanne Hendrix, PhD; Enchi Liu, PhD; David A. Loewenstein, PhD; Glenn Morrison, MSc, PhD; Leslie Shinobu, PhD; Keith Wesnes, BSc, PhD, FSS, CPsychol, FBPsS; and Philip D. Harvey, PhD Dr. Posner is with Pfizer Inc., New York, New York; Drs. Curiel, Loewenstein, and Harvey […]

Continue Reading

Performance-based and Observational Assessments in Clinical Trials Across the Alzheimer’s Disease Spectrum

Performance-based and Observational Assessments in Clinical Trials Across the Alzheimer’s Disease Spectrum

| February 1, 2017 | 0 Comments

by Philip D. Harvey, PhD; Stephanie Cosentino, PhD; Rosie Curiel, PhD; Terry E. Goldberg, PhD; Jeffrey Kaye, MD; David Loewenstein, PhD; Daniel Marson, PhD, JD; David Salmon, PhD; Keith Wesnes, PhD; and Holly Posner, MD Drs. Harvey, Curiel, and Loewenstein are with the University of Miami Leonard Miller School of Medicine, Department of Psychiatry and Behavioral Sciences, Miami, Florida; […]

Continue Reading